FDA panel backs broader access to six peptides through compounding pharmacies

An FDA advisory committee voted to recommend expanding access to six peptides (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon) by adding them to the 503A Bulks List, potentially enabling licensed pharmacies to prepare prescriptions instead of relying on unregulated online sources. The vote covers six of seven peptides reviewed; the FDA must still issue a final decision. While supporters view it as progress toward safer access, experts caution that safety and efficacy data vary across peptides and emphasize requiring qualified clinicians, licensed pharmacies, quality testing, and patient monitoring—without treating this as blanket approval.